Palvella Therapeutics (NASDAQ:PVLA) Stock Price Down 4.9% – Here’s What Happened

Palvella Therapeutics, Inc. (NASDAQ:PVLA) shares were down 4.9% on Friday . The stock traded as low as $97.19 and last traded at $99.50. 58,985 shares were traded during mid-day trading, a decline of 79% from the average session volume of 286,174 shares. The stock had previously closed at $104.67.

Analysts Set New Price Targets

A number of research firms have commented on PVLA. Raymond James Financial restated a “strong-buy” rating and issued a $193.00 price target on shares of Palvella Therapeutics in a research report on Tuesday, December 16th. Weiss Ratings reiterated a “sell (d)” rating on shares of Palvella Therapeutics in a research note on Monday. TD Cowen increased their price target on Palvella Therapeutics from $97.00 to $133.00 and gave the stock a “buy” rating in a research report on Tuesday, December 16th. Chardan Capital raised their price target on Palvella Therapeutics from $110.00 to $174.00 and gave the company a “buy” rating in a report on Monday, December 15th. Finally, Truist Financial increased their target price on Palvella Therapeutics from $105.00 to $190.00 and gave the stock a “buy” rating in a report on Monday, December 15th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $155.60.

Palvella Therapeutics Trading Down 0.8%

The stock has a market cap of $1.23 billion, a price-to-earnings ratio of -39.49 and a beta of -0.16. The firm has a fifty day simple moving average of $91.09 and a 200-day simple moving average of $62.09.

Palvella Therapeutics (NASDAQ:PVLA) last released its earnings results on Monday, November 10th. The company reported ($1.03) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.18). On average, equities analysts predict that Palvella Therapeutics, Inc. will post -3.69 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,302 shares of the business’s stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $96.47, for a total transaction of $415,013.94. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 20.50% of the company’s stock.

Institutional Investors Weigh In On Palvella Therapeutics

Institutional investors have recently modified their holdings of the business. Archer Investment Corp bought a new stake in shares of Palvella Therapeutics during the third quarter worth approximately $28,000. Russell Investments Group Ltd. bought a new position in Palvella Therapeutics in the third quarter valued at approximately $36,000. Police & Firemen s Retirement System of New Jersey acquired a new stake in Palvella Therapeutics during the 2nd quarter worth $37,000. AlphaQuest LLC bought a new stake in shares of Palvella Therapeutics during the 3rd quarter valued at $164,000. Finally, JPMorgan Chase & Co. raised its position in shares of Palvella Therapeutics by 108,066.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock valued at $73,000 after acquiring an additional 3,242 shares during the last quarter. Institutional investors and hedge funds own 40.11% of the company’s stock.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.